Tablet for Field Instrument Management
Endress+Hauser’s Field Xpert SMT70 is a tablet PC suited for commissioning and maintaining field instruments in hazardous and non-hazardous locations.
Endress+Hauser’s Field Xpert SMT70 is a tablet PC suited for commissioning and maintaining field instruments in hazardous and non-hazardous locations. The device can connect to field instrumentation devices directly via USB or Bluetooth wireless modem, or via a gateway, remote I/O, or multiplexer to a bus system. Other communication ports and supported networks include Ethernet, HDMI, and Wi-Fi, with 4G LTE and GPS available.
The tablet comes preinstalled with DeviceCare device configuration software and a device library that contains more than 2700 pre-installed device and communication drivers, allowing it to work with different instruments from a variety of vendors.
The drivers can be used to communicate with virtually all Highway Addressable Remote Transducer (HART) and Foundation Fieldbus devices, and additional device drivers (DTMs) can be installed if required, according to the company. Generic HART DTM and Process Field Bus Decentralized profile DTMs also enable communication with field devices using these protocols. Other supported service interfaces include Modbus, Contexts and Dependency Injection, and Endress+Hauser. The tablet comes in a general-purpose configuration as well hazardous area configuration for Class 1, Division 2 Groups A, B, C, D, T4, and Class 1, Zone 2, Groups IIC, T4.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
